Principal Securities, Inc. Innate Pharma Sa Transaction History
Principal Securities, Inc.
- $5.32 Trillion
- Q2 2025
A detailed history of Principal Securities, Inc. transactions in Innate Pharma Sa stock. As of the latest transaction made, Principal Securities, Inc. holds 45 shares of IPHA stock, worth $94. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45Holding current value
$94% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IPHA
# of Institutions
10Shares Held
99.8KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY51.2KShares$107,5700.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il26.6KShares$55,8950.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny11.7KShares$24,4880.0% of portfolio
-
Ubs Group Ag5.96KShares$12,5090.0% of portfolio
-
Gamma Investing LLC Foster City, CA3.46KShares$7,2570.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $168M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...